Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.

Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.

PMID:
28287331
2.

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.

Ann Neurol. 2013 Jan;73(1):95-103. doi: 10.1002/ana.23758.

PMID:
23378325
3.

Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients.

Romeo M, Martinelli V, Rodegher M, Perego E, Maida S, Sormani MP, Comi G; San Raffaele Multiple Sclerosis Clinical Group.

Eur J Neurol. 2015 Jun;22(6):973-80. doi: 10.1111/ene.12695. Epub 2015 Apr 6.

PMID:
25846708
4.

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.

JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.

PMID:
22797642
5.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
6.

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002 Apr;8(2):119-23.

PMID:
11990868
7.

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.

BMC Neurol. 2019 Jun 8;19(1):116. doi: 10.1186/s12883-019-1337-z.

9.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
10.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
11.

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.

Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Dobson C.

Lancet Neurol. 2015 May;14(5):497-505. doi: 10.1016/S1474-4422(15)00018-6. Epub 2015 Apr 1.

PMID:
25841667
12.

New natural history of interferon-beta-treated relapsing multiple sclerosis.

Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.

Ann Neurol. 2007 Apr;61(4):300-6.

PMID:
17444502
13.

Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL.

JAMA Neurol. 2015 Feb;72(2):152-8. doi: 10.1001/jamaneurol.2014.3537.

PMID:
25531931
14.

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.

Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.

Health Technol Assess. 2016 Oct;20(81):1-48.

15.

No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.

Huhn K, Senger D, Utz KS, Schmidt M, Fröhlich K, Waschbisch A, Seifert F, Dörfler A, Lee DH, Linker RA.

Mult Scler Relat Disord. 2019 Jan;27:133-138. doi: 10.1016/j.msard.2018.10.020. Epub 2018 Oct 23.

PMID:
30384198
16.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

17.

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M, Mainero C, Horsfield M, Galgani S, Bastianello S, Buttinelli C.

Eur J Neurol. 2002 Nov;9(6):645-55.

PMID:
12453081
18.

Scoring treatment response in patients with relapsing multiple sclerosis.

Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, Stubinski B, Stromillo Ml, Montalban X, De Stefano N.

Mult Scler. 2013 Apr;19(5):605-12. doi: 10.1177/1352458512460605. Epub 2012 Sep 25.

PMID:
23012253
19.
20.

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.

O'Rourke K, Walsh C, Antonelli G, Hutchinson M.

Mult Scler. 2007 Apr;13(3):336-42. Epub 2007 Jan 29.

PMID:
17439902

Supplemental Content

Support Center